TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an...
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July...
New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the...
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain...
New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...
New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...
0001851484 false Q1 --12-31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 &nb...
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number:3235-0145 Expires:Febuary 28...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads